Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics priced a $300 million underwritten offering of 23,871,526 shares of common stock at $11.52 per share. The offering also includes pre-funded warrants to purchase 2,170,138 shares at $11.5199 per share, which is slightly below the offering price. Proceeds from the offering are expected to be approximately $300 million, before deducting underwriting discounts and commissions.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.